On January 1, 2021, Wang, Yuhong; Mi, Tian; Li, Yiming; Kan, Weijuan; Xu, Gaoya; Li, Jingya; Zhou, Yubo; Li, Jia; Jiang, Xuefeng published an article.Name: 1-Decanethiol The title of the article was Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity. And the article contained the following:
In this work, the designed lenalidomides I [R = Et, Ph, 2-naphthyl, etc.; X = S, Se] and pomalidomides II [R1 = Et, pentyl, hexyl, 4-MeC6H4, 6-chloro-2-pyridyl; Y = S, Se] were synthesized and evaluated. The anti-proliferative activity against MM.1S cell line of compound I [R = 4-FC6H4, X = S] (IC50 = 79 nM) was similar to lenalidomide (IC50 = 81 nM). Compared to compound I [R = 4-F3CC6H4CH2], the half-live (T1/2) of compound I [R = 4-FC6H4, X = S] in human liver microsomes was promoted from 3 min to 416.7 min. The corresponding metabolic factor of compound I [R = 4-FC6H4, X = S] was increased from 2.8% to 79.5%, which was slightly lower than lenalidomide (91.5%). Moreover, the IKZF1 degradation of compounds I [R = 2-MeOC6H4, 4-FC6H4, X = S] was well related with corresponding IC50 values, which suggested the IKZF1 degradation efficiency was correlated to the responses of MM1.S cells. Furthermore, the oral administration of compounds I [R = 2-MeOC6H4, 4-FC6H4, X = S] at dosages of 60 mg/kg could delay tumor growth in female CB-17 SCID mice. This research helped to prompt the stability of thioether lenalidomide analogs, which paved the way for developing better mols. for treating multiple myeloma. The experimental process involved the reaction of 1-Decanethiol(cas: 143-10-2).Name: 1-Decanethiol
The Article related to thioether containing lenalidomide preparation antitumor human sar, pomalidomide thioether containing preparation antitumor human sar, late-stage sulfuration, lenalidomide, mm.1s, multiple myeloma and other aspects.Name: 1-Decanethiol
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts